Inventor · disambiguated record
Birgit Bossenmaier
Also filed as: BOSSENMAIER BIRGIT
31 granted patents·12 pending applications·89 citations·filing 2003–2020
95Inventor score
Files withHOFFMANN LA ROCHE23BOSSENMAIER BIRGIT10ROCHE GLYCART AG6AUER JOHANNES1PIERIS PHARMACEUTICALS GMBH1
Top patents by PatentIndex Score
43 records- 0191US10611825B2Monovalent antigen binding proteinsHOFFMANN LA ROCHE·Filed 2017·Granted Apr 7, 2020·6 cites·8 claims
- 0291US9982036B2Dual FC antigen binding proteinsBOSSENMAIER BIRGIT·Filed 2012·Granted May 29, 2018·12 cites·3 claims
- 0388US9180185B2Combination therapy of anti-HER3 antibodiesHOFFMANN LA ROCHE·Filed 2014·Granted Nov 10, 2015·13 cites·15 claims
- 0485US9346886B2Humanized anti-CDCP1 antibodiesROCHE GLYCART AG·Filed 2012·Granted May 24, 2016·8 cites·2 claims
- 0582US9725512B2HER3 antibodies binding to the beta-hairpin of HER3HOFFMANN LA ROCHE·Filed 2013·Granted Aug 8, 2017·5 cites·8 claims
- 0682US7235574B2Pentafluorosulfanyl compoundsHOFFMANN LA ROCHE·Filed 2005·Granted Jun 26, 2007·6 cites·15 claims
- 0781US7163953B2Benzylether derivativesHOFFMANN LA ROCHE·Filed 2005·Granted Jan 16, 2007·4 cites·11 claims
- 0880US8883159B2Antibodies against CDCP1 for the treatment of cancerBOSSENMAIER BIRGIT·Filed 2010·Granted Nov 11, 2014·4 cites·10 claims
- 0980US8394928B2Humanized anti-CDCP1 antibodiesAUER JOHANNES·Filed 2010·Granted Mar 12, 2013·7 cites·33 claims
- 1078US7005526B2Thioether derivativesHOFFMANN LA ROCHE·Filed 2005·Granted Feb 28, 2006·3 cites·16 claims
- 1177US8859737B2Anti-HER3 antibodies and uses thereofBOSSENMAIER BIRGIT·Filed 2010·Granted Oct 14, 2014·3 cites·7 claims
- 1277US7429605B2Phenylpyridine derivativesHOFFMANN LA ROCHE·Filed 2006·Granted Sep 30, 2008·4 cites·38 claims
- 1377US7405231B2Oxidized thioether derivativesHOFFMANN LA ROCHE·Filed 2005·Granted Jul 29, 2008·2 cites·18 claims
- 1475US7432291B2Ether derivativesHOFFMANN LA ROCHE·Filed 2005·Granted Oct 7, 2008·2 cites·17 claims
- 1572US9611331B2Anti-HER3 antibodies and uses thereofROCHE GLYCART AG·Filed 2014·Granted Apr 4, 2017·1 cites·13 claims
- 1671US9725511B2Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4HOFFMANN LA ROCHE·Filed 2013·Granted Aug 8, 2017·1 cites·17 claims
- 1770US9339560B2Method for determining the anti-tumor efficacy of monoclonal antibodiesBOSSENMAIER BIRGIT·Filed 2009·Granted May 17, 2016·0 cites·2 claims
- 1868US9840565B2HER1 antigen binding proteins binding to the beta-hairpin of HER1HOFFMANN LA ROCHE·Filed 2015·Granted Dec 12, 2017·1 cites·14 claims
- 1968US7247649B2Oxazoles, their manufacture and use as pharmaceutical agentsHOFFMANN LA ROCHE·Filed 2004·Granted Jul 24, 2007·3 cites·5 claims
- 2064US9783611B2Anti-HER3 antibodies binding to the beta-hairpin of HER3HOFFMANN LA ROCHE·Filed 2015·Granted Oct 10, 2017·1 cites·9 claims
- 2162US10793621B2Nucleic acid encoding dual Fc antigen binding proteinsHOFFMANN LA ROCHE·Filed 2018·Granted Oct 6, 2020·0 cites·5 claims
- 2262US10626177B2HER3 antigen binding proteins binding to the beta-hairpin of HER3HOFFMANN LA ROCHE·Filed 2017·Granted Apr 21, 2020·0 cites·13 claims
- 2362US7205325B2Oxazole derivativesHOFFMANN LA ROCHE·Filed 2004·Granted Apr 17, 2007·1 cites·14 claims
- 2462US2013156772A1Bispecific Anti ErbB1 / Anti cMet AntibodiesROCHE GLYCART AG·Filed 2013·Application pending·0 cites
- 2562US2013273054A1Bispecific Anti ErbB2/Anti cMet AntibodiesROCHE GLYCART AG·Filed 2013·Application pending·0 cites
- 2659US10196456B2Anti-HER3 antibodies and uses thereofROCHE GLYCART AG·Filed 2017·Granted Feb 5, 2019·0 cites·13 claims
- 2759US7259262B2Arylazole derivatives, their manufacture and use as pharmaceutical agentsHOFFMANN LA ROCHE·Filed 2004·Granted Aug 21, 2007·1 cites·18 claims
- 2859US7205326B2Aniline derivatives, their manufacture and use as pharmaceutical agentsHOFFMANN LA ROCHE·Filed 2004·Granted Apr 17, 2007·1 cites·25 claims
- 2957US2004106161A1Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodiesFiled 2003·Application pending·0 cites
- 3055US2014135482A1Bispecific Anti ErbB3 / Anti cMet AntibodiesROCHE GLYCART AG·Filed 2014·Application pending·0 cites
- 3154US10364290B2Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4HOFFMANN LA ROCHE·Filed 2017·Granted Jul 30, 2019·0 cites·16 claims
- 3254US2010254988A1Bispecific Anti ErbB2 / Anti cMet AntibodiesBOSSENMAIER BIRGIT·Filed 2010·Application pending·0 cites
- 3354US2010254989A1Bispecific Anti ErbB1 / Anti c Met AntibodiesBOSSENMAIER BIRGIT·Filed 2010·Application pending·0 cites
- 3449US10808038B2HER3/HER2 bispecific antibodies binding to the beta-hairpin of HER3 and domain II of HER2HOFFMANN LA ROCHE·Filed 2016·Granted Oct 20, 2020·0 cites·6 claims
- 3549US10179815B2Antibodies specifically binding to HER3ROCHE MOLECULAR SYSTEMS INC·Filed 2016·Granted Jan 15, 2019·0 cites·20 claims
- 3649US2012237507A1Monovalent Antigen Binding ProteinsBOSSENMAIER BIRGIT·Filed 2012·Application pending·0 cites
- 3747US2018100022A1Her1 antigen binding proteins binding to the beta-hairpin of her1HOFFMANN LA ROCHE·Filed 2017·Application pending·0 cites
- 3846US2011117096A1Methods for Identifying Tumors That are Responsive to Treatement With Anti-ErbB2 AntibodiesBOSSENMAIER BIRGIT·Filed 2010·Application pending·0 cites
- 3945US12486330B2Fusion proteins specific for CD137 and GPC3PIERIS PHARMACEUTICALS GMBH·Filed 2020·Granted Dec 2, 2025·0 cites·6 claims
- 4044US2006116407A1Amide derivativesBOSSENMAIER BIRGIT·Filed 2005·Application pending·0 cites
- 4144US2010256339A1Bispecific Anti ErbB3 / Anti cMet AntibodiesBOSSENMAIER BIRGIT·Filed 2010·Application pending·0 cites
- 4241US7179812B2Diazine derivativesHOFFMANN LA ROCHE·Filed 2005·Granted Feb 20, 2007·0 cites·13 claims
- 4341US2016159912A1Combination therapy of anti-her3 antibodiesHOFFMANN LA ROCHE·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Birgit Bossenmaier files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →